Announcements
- Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
- Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
- Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
- Cabaletta Bio to Participate in Upcoming Investor Conferences in March
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
- Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
- Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 174.22 |
---|---|
High | 174.88 |
Low | 174.22 |
Bid | 174.88 |
Offer | -- |
Previous close | 170.35 |
Average volume | 340.00 |
---|---|
Shares outstanding | 48.28m |
Free float | 45.05m |
P/E (TTM) | -- |
Market cap | 491.94m USD |
EPS (TTM) | -1.73 USD |
Data delayed at least 20 minutes, as of May 31 2024 15:25 BST.
More ▼